Acute Liver Failure after Treatment with Rivaroxaban for Aortic Thrombosis Associated with COVID-19 Infection and Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T)

Ivana Jukic; Dorotea Bozic; Milos Lalovac; Mirela Pavicic Ivelja; Mislav Radic; Zeljko Sundov; Jonatan Vukovic

doi:10.1159/000524791

Acute Liver Failure after Treatment with Rivaroxaban for Aortic Thrombosis Associated with COVID-19 Infection and Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T)

Case Rep Gastroenterol. 2022 May 23;16(2):320-325. doi: 10.1159/000524791. eCollection 2022 May-Aug.

Authors

Ivana Jukic¹, Dorotea Bozic¹, Milos Lalovac², Mirela Pavicic Ivelja³, Mislav Radic⁴, Zeljko Sundov¹, Jonatan Vukovic¹

Affiliations

¹ Department of Gastroenterology and Hepatology, University Hospital of Split, Split, Croatia.
² Department of Gastroenterology and Hepatology, Merkur University Hospital, Zagreb, Croatia.
³ Department of Infectious Diseases, University Hospital of Split, Split, Croatia.
⁴ Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, Split, Croatia.

Abstract

Coronavirus disease-2019 (COVID-19) has become associated with prothrombotic state that could lead to severe arterial thrombotic complications. In the case of severe COVID-19 infection, hepatic dysfunction has been observed in more than 50% of patients. In this article, we present a case of aortic thrombosis associated with COVID-19 infection and methylenetetrahydrofolate reductase gene polymorphism (C677T) treated with rivaroxaban resulting in acute liver failure with fatal outcome.

Keywords: Acute liver failure; Arterial thrombosis; COVID-19; Rivaroxaban; Thrombophilia.

Publication types

Case Reports